Course: COVID-19 “Liquid Biopsy” Could Offer Monitoring, Prognostic Tool
CME Credits: 1.00
Released: 2021-03-09
Cornell University researchers are developing a “liquid biopsy” that detects and quantifies injury to internal organs from coronavirus disease 2019 (COVID-19). The test profiles epigenetic changes in circulating cell-free DNA (cfDNA)—small fragments of genetic material from dead cells, including those killed off by infection or immune-related injury. The DNA chemical modifications are specific to different cell, tissue, and organ types, revealing the origin of injury.
In a recent , published in Med, researchers analyzed cfDNA in 104 plasma samples from 33 patients with COVID-19 at 2 North American hospitals. They compared their cfDNA profiles with those from patients with other viral infections and a control group of healthy individuals.
Educational Objective
To identify the key insights or developments described in this article
View Full Course